Brief: Newron Pharmaceuticals Says FDA Grants Rare Pediatric Disease Designation For Sarizotan
19/11/2019 06:58
Nov 19 (Reuters) - NEWRON PHARMACEUTICALS SPA NWRN.S :
* U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS GRANTED RARE
PEDIATRIC DISEASE DESIGNATION FOR SARIZOTAN
Source text https://bit.ly/2KxxDXW
Further company coverage: NWRN.S
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;;))
Recent news on Newron Pharmaceuticals SpA
See all newsUS FDA flags four deaths in Newron's schizophrenia drug studies (updated)
US FDA cites 4 deaths in Newron's schizophrenia drug trial hold
Brief: Newron Says Topline Data From ENIGMA-TRS 1 Expected In Q1 2027
Brief: Newron Provides Update Following Type A Meeting With The FDA
Brief: Newron Reports Pause Of Enrollment Of New Study Participants In US Centers Of ENIGMA-TRS 2 Study